Safety and Survival Associated with Biologic Therapies: First Report of the Biobadaguay on the Paraguayan-Uruguayan Registry of Adverse Events with Biologic Therapies
Reumatol Clin (Engl Ed). 2020 Sep-Oct;16(5 Pt 2):396-404.
doi: 10.1016/j.reuma.2018.08.009.
Epub 2018 Dec 27.
[Article in
English,
Spanish]
Authors
Paloma de Abreu
1
, Gabriela Ávila-Pedretti
2
, Zoilo Morel
3
, María Isabel Acosta
4
, Sonia Cabrera-Villalba
3
, Patricia Melgarejo
2
, Marco Franco
2
, Pedro Delgadillo
2
, Lourdes Román
4
, Juan Gabriel Elizaur
2
, Ernesto Paredes
2
, Darwin Octavio Cordovilla
5
, Daniel Palleiro
5
, Miguel Albanese
5
, Julio Mazzoleni
2
Affiliations
- 1 Sociedad Paraguaya de Reumatología, Asunción, Paraguay. Electronic address: pdeabreut@gmail.com.
- 2 Hospital Central del Instituto de Previsión Social, Asunción, Paraguay.
- 3 Hospital Central del Instituto de Previsión Social, Asunción, Paraguay; Hospital de Clínicas Universidad Nacional de Asunción, Asunción, Paraguay.
- 4 Hospital de Clínicas Universidad Nacional de Asunción, Asunción, Paraguay.
- 5 Instituto Nacional de Reumatología, Montevideo, Uruguay.
Abstract
Objective:
Analyze adverse events (AE) and survival associated with biologic therapies (BT) in the Biobadaguay, the Paraguayan Uruguayan registry of adverse events.
Methods:
Prospective, observational study of undetermined duration. Patients on BT at initiation and controls were included. Clinical, biological and treatment variables were registered.
Results:
A total of 826 registers were entered (650 BT and 176 controls); 70.9% were women and rheumatoid arthritis (RA) was the most frequent diagnosis (63.2%). The BT most often used was adalimumab and the main cause of discontinuation was loss of efficacy (42.1%). The incidence of AE of patients on BT was 143.9 (128.8-160.8) per 1000 patients/year. In the comparative study of AE related to diagnosis, juvenile idiopathic arthrosis (JIA) was associated with a higher overall number of AE (RTI = 2.3; 95%CI: 1.6-3.4; P = 4.27 ×10-6), whereas RA was associated with a higher number of serious AE (RTI = 2.2; 95% CI: 1.2-4.1; P =1.17 ×10-2). On the other hand, treatment with tocilizumab was associated with a higher rate of AE (RTI = 2.69; 95% CI: 1.9-3.82; P = 3.13 ×10-8). In JIA, treatment with corticosteroids and number of previous BT was associated with a decrease in BT survival.
Conclusion:
In this first report of the Biobadaguay registry, the main cause of BT discontinuation was loss of efficacy. In terms of the diagnosis involved, RA and JIA were associated with a higher risk of AE. In this registry, variables related to a shorter survival of BT were identified.
Keywords:
Biological therapy; Registro; Registry; Safety; Seguridad; Supervivencia; Survival; Terapia biológica.
Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.
MeSH terms
-
Adalimumab / adverse effects
-
Adalimumab / therapeutic use*
-
Adult
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Juvenile / drug therapy*
-
Arthritis, Juvenile / mortality
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / mortality
-
Biological Products / adverse effects
-
Biological Products / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Paraguay
-
Prospective Studies
-
Registries
-
Survival Rate
-
Uruguay
Substances
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Biological Products
-
Adalimumab
-
tocilizumab